Keyword

abciximab

Description: A monoclonal antibody drug that blocks platelet glycoprotein IIb/IIIa receptors to inhibit platelet aggregation, especially during coronary procedures.

Primary topic: Antiplatelet Therapy and Cardiovascular Diseases (37%)

Wikidata ID: wiki/Q307088

OpenAlex ID: keywords/abciximab

Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease

2004 · Jane W. Newburger, Masato Takahashi, et al. · Circulation · 1,938

PDF

Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization

1997 · The EPILOG Investigators · New England Journal of Medicine · 1,883

PDF

Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association

2004 · Jane W. Newburger, Masato Takahashi, et al. · PEDIATRICS · 1,433

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

1998 · T Epistent Investigators · The Lancet · 1,346

Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study

1997 · CAPTURE, STGRP, non vooting member Tijssen, J. · The Lancet · 1,327

PDF

Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction

2002 · Gregg W. Stone, Cindy L. Grines, et al. · New England Journal of Medicine · 1,277

PDF

Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction

2001 · Gilles Montalescot, Paul Barragan, et al. · New England Journal of Medicine · 1,186

PDF

Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention

2003 · A. Michael Lincoff, John A. Bittl, et al. · JAMA · 1,162

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

1998 · Eric J Topol · The Lancet · 1,095

Soluble CD40 Ligand in Acute Coronary Syndromes

2003 · Christopher Heeschen, Stefanie Dimmeler, et al. · New England Journal of Medicine · 828

PDF

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

2001 · The Lancet · 765

Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19

2020 · Eugenio D. Hottz, Isaclaudia G. Azevedo-Quintanilha, et al. · Blood · 751

PDF

Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment The ISAR-REACT 2 Randomized Trial

2006 · Adnan Kastrati · JAMA · 751

Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction

1998 · Sorin J. Brener, Lawrence A. Barr, et al. · Circulation · 722

Benefit of Abciximab in Patients with Refractory Unstable Angina in Relation to Serum Troponin T Levels

1999 · Christian W. Hamm, Christopher Heeschen, et al. · New England Journal of Medicine · 710

PDF

Facilitated PCI in Patients with ST-Elevation Myocardial Infarction

2008 · Stephen G. Ellis, Michal Tendera, et al. · New England Journal of Medicine · 696

PDF

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial

2001 · M L Simoons · The Lancet · 690

TEG and ROTEM: Technology and clinical applications

2013 · David Whiting, James A. DiNardo · American Journal of Hematology · 688

PDF

Abciximab Facilitates the Rate and Extent of Thrombolysis

1999 · Elliott M. Antman, Robert P. Giugliano, et al. · Circulation · 681

PDF

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial

2001 · E J Topol · The Lancet · 680

Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization

2001 · Eric J. Topol, David J. Moliterno, et al. · New England Journal of Medicine · 677

PDF

Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction

2005 · Giuseppe De Luca, Harry Suryapranata, et al. · JAMA · 614

Drug-Induced Immune Thrombocytopenia

2007 · Richard H. Aster, Daniel W. Bougie · New England Journal of Medicine · 587

A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel

2004 · Adnan Kastrati, Julinda Mehilli, et al. · New England Journal of Medicine · 568

PDF

Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction

2012 · Gregg W. Stone · JAMA · 541

Works count: 3,818

Citation count: 96,980